DIN 02496976 — BEOVU 6 MG
BEOVU is a solution of Brolucizumab marketed by NOVARTIS PHARMACEUTICALS CANADA INC. The full Brolucizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02496976
- Brand name
- BEOVU
- Active ingredient
- Brolucizumab
- Strength
- 6 MG
- Dosage form
- SOLUTION
- Route
- INTRAVITREAL
- Manufacturer
- NOVARTIS PHARMACEUTICALS CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Anti-vascular endothelial growth factor (anti-VEGF-A) inhibitor
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.